STERIS (STE) Hisse Özeti
STERIS plc dünya çapında enfeksiyon önleme ürünleri ve hizmetleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 4/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden STE için herhangi bir risk tespit edilmedi.
STE Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
STERIS plc Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$212.25 |
| 52 Haftanın En Yüksek Seviyesi | US$269.44 |
| 52 Haftanın En Düşük Seviyesi | US$209.98 |
| Beta | 1.07 |
| 1 Aylık Değişim | -2.95% |
| 3 Aylık Değişim | -18.89% |
| 1 Yıllık Değişim | -5.37% |
| 3 Yıllık Değişim | 12.31% |
| 5 Yıllık Değişim | 2.22% |
| Halka arzdan bu yana değişim | 10,190.91% |
Son Haberler & Güncellemeler
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.Is There Now An Opportunity In STERIS plc (NYSE:STE)?
Mar 24
STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.Recent updates
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.Is There Now An Opportunity In STERIS plc (NYSE:STE)?
Mar 24STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside
Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View
Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.STERIS: A Bump In The Road For A Reliable Name
Feb 06STE: Share Repurchases And Stable Outlook Will Support A Fair View
Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook
Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors
Jan 09Earnings Tell The Story For STERIS plc (NYSE:STE)
Dec 26STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook
Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook
Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance
Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value
Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.Is STERIS (NYSE:STE) A Risky Investment?
Oct 27Healthcare Demand And Facility Expansion Will Create Value
With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.Calculating The Fair Value Of STERIS plc (NYSE:STE)
Aug 28STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year
Aug 07Is There Now An Opportunity In STERIS plc (NYSE:STE)?
Jul 06Is Now The Time To Put STERIS (NYSE:STE) On Your Watchlist?
May 23Is There An Opportunity With STERIS plc's (NYSE:STE) 33% Undervaluation?
May 07Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Mar 22Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Nov 18Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Sep 16
Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector
Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.Steris: Q2 Numbers Solidify Buy Thesis
Aug 13Hissedar Getirileri
| STE | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -4.5% | -5.0% | 0.6% |
| 1Y | -5.4% | -19.0% | 28.4% |
Getiri vs. Endüstri: STE geçen yıl % -19 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: STE geçen yıl % 28.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| STE volatility | |
|---|---|
| STE Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: STE son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: STE 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1985 | 17,787 | Dan Carestio | www.steris.com |
STERIS plc dünya çapında enfeksiyon önleme ürünleri ve hizmetleri sunmaktadır. Üç segmentte faaliyet göstermektedir: Sağlık Hizmetleri, Uygulamalı Sterilizasyon Teknolojileri (AST) ve Yaşam Bilimleri. Sağlık Hizmetleri segmenti, temizlik kimyasalları ve sterilite güvence ürünleri; otomatik endoskop yeniden işleme sistemi ve izleme ürünleri; endoskopi aksesuarları, yıkayıcılar, sterilizatörler ve steril işleme departmanının çalışması için diğer sermaye ekipmanı parçaları; ve cerrahi masalar, ışıklar ve bağlantı çözümleri dahil olmak üzere doğrudan prosedür odalarında kullanılan ekipman ve ekipman yönetimi hizmetleri sunmaktadır.
STERIS plc Temel Bilgiler Özeti
| STE temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$21.03b |
| Kazançlar(TTM) | US$708.52m |
| Gelir(TTM) | US$5.83b |
29.4x
F/K Oranı3.6x
P/S OranıSTE aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| STE gelir tablosu (TTM) | |
|---|---|
| Gelir | US$5.83b |
| Gelir Maliyeti | US$3.24b |
| Brüt Kâr | US$2.58b |
| Diğer Giderler | US$1.87b |
| Kazançlar | US$708.52m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
May 11, 2026
| Hisse başına kazanç (EPS) | 7.22 |
| Brüt Marj | 44.32% |
| Net Kâr Marjı | 12.16% |
| Borç/Özkaynak Oranı | 26.5% |
STE uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.2%
Mevcut Temettü Verimi33%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/04 19:45 |
| Gün Sonu Hisse Fiyatı | 2026/05/04 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
STERIS plc 21 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |
| David Turkaly | Citizens JMP Securities, LLC |